Director/PDMR Shareholding

RNS Number : 2864Y

Creo Medical Group PLC

20 August 2018

 

Creo Medical Group plc (the "Company")

Director/PDMR Dealing

The Company announces that on 17 August 2018, the Company was informed that, on 17 August and 15 August 2018 respectively, Craig Gulliford, Chief Executive Officer, and Chris Hancock, Chief Technology Officer, had part of their shareholdings dematerialised by a third party in order to procure that those shares are capable of being held in CREST. This process meant the transfer of a total of 960,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") (representing 480,000 Ordinary Shares each) to Wealth Nominees Limited.

Following these transfers, Messrs Gulliford's and Hancock's beneficial interests in Ordinary Shares remain unchanged.

Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Craig Gulliford
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	ordinary shares of 0.1 pence each GB00BZ1BLL44
b)	Nature of the transaction	Exercise of shares options and subsequent transfer of ordinary shares to SIPP via sale and purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) Transfer for nil consideration 480,000
d)	Aggregated information - Aggregated volume - Price	Transfer for nil consideration of 480,000 ordinary shares of 0.1 pence each to Wealth Nominees Limited in order to allow for such shares to be dematerialised and held in CREST
e)	Date of the transaction	17 August 2018
f)	Place of the transaction	Off Market

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Christopher Hancock
2	Reason for the notification
a)	Position/status	Chief Technical Officer
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Creo Medical Group plc
b)	LEI	213800H188ZDCWWXFA21
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	ordinary shares of 0.1 pence each GB00BZ1BLL44
b)	Nature of the transaction	Exercise of shares options and subsequent transfer of ordinary shares to SIPP via sale and purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) Transfer for nil consideration 480,000
d)	Aggregated information - Aggregated volume - Price	Transfer for nil consideration of 480,000 ordinary shares of 0.1 pence each to Wealth Nominees Limited in order to allow for such shares to be dematerialised and held in CREST
e)	Date of the transaction	15 August 2018
f)	Place of the transaction	Off Market

Contacts

Creo Medical:	Cenkos:	FTI Consulting:
Richard Rees [phone] [e-mail]	Mark Connelly (NOMAD) Michael Johnson / Russell Kerr (Sales) [phone]	Brett Pollard / Mo Noonan [phone] [e-mail]

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

 

END

 

 

DSHLIFLATIIIFIT